Seaport Therapeutics (SPTX) Q2 2026 earnings summary

Executive summary

• Focused on developing oral therapies for neuropsychiatric disorders using the proprietary Glyph platform, with lead candidates in major depressive disorder (MDD) and generalized anxiety disorder (GAD).

• Achieved positive Phase 1 proof-of-concept results for GlyphAgo and advanced clinical pipeline with ongoing trials for GlyphAllo (MDD) and GlyphAgo (GAD), plus preclinical progress for Glyph2BLSD.

• Completed IPO in Q2 2026, raising $238.4 million in net proceeds and $260M in gross proceeds; all preferred stock converted to common stock.

• Significant operating losses continue as the company invests in R&D and public company infrastructure.

• Strengthened leadership with the appointment of Sharon Mates, Ph.D., to the Board of Directors.

Financial highlights

• Net loss for six months ended June 30, 2026: $88.0 million, up from $28.2 million year-over-year.

• Cash, cash equivalents, and investments as of June 30, 2026: $427.3 million, expected to fund operations into 2029.

• R&D expenses for Q2 2026: $24.6 million, up from $13.4 million in Q2 2025; G&A expenses rose to $41.2 million from $5.1 million year-over-year, mainly due to IPO-related stock-based compensation.

• No revenue from product sales; other income primarily from interest and R&D tax credits.

• Stock-based compensation expense for six months: $39.4 million, driven by IPO-related grants and accelerated vesting.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2029 based on current plans.

• Topline data for GlyphAllo Phase 2b expected in H1 2027; Phase 1 driving simulation data in 2H 2026.

• GlyphAgo Phase 2a trial in GAD and sleep disturbance to start in 2H 2026, topline data in early 2028; Phase 2b GAD trial to start in 1H 2027, topline data by year-end 2028.

• First-in-human enabling studies for Glyph2BLSD expected to complete by end of 2027.

• No expectation of product revenue in the near term; future funding needs anticipated for late-stage development and commercialization.